Recent studies have found that gefitinib, an inhibitor of EGF receptor (EGFR), can significantly improve peritoneal fibrosis in experimental mouse models by inhibiting STAT3 phosphorylation.21 Here, STAT3 is linked to Peritoneal Fibrosis.